Table 2

UVA and MVA* analyses of mGPS and survival outcomes

VariableUVAMVA*
OSPFSOSPFS
HR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P value
Baseline mGPS2
(n=37)
4.29 (2.24–8.24)<0.001†1.90 (1.20–3.01)0.006†3.61 (1.78–7.31)<0.001†1.87 (1.17–2.97)0.008†
1
(n=62)
2.78 (1.49–5.17)0.001†1.33 (0.88–2.01)0.1831.82 (0.94–3.54)0.0761.19 (0.77–1.85)0.435
0
(n=57)
  • *The Cox proportional hazard model was fitted followed by backward variable elimination with a significance level of p<0.1. The covariables controlled for included age, sex, race, baseline Body Mass Index, sites of metastases, ECOG performance status, clear cell histology and prior lines of therapy.

  • †Statistical significance at alpha<0.05.

  • ECOG, Eastern Cooperative Oncology Group; mGPS, modified Glasgow Prognostic Score; MVA, multivariate analysis; OS, overall survival; PFS, progression-free survival; UVA, univariate analysis.